


Amendments to the Claims

Please add new Claims 46-49. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Previously presented) A method of treating a patient suffering from or susceptible to an RSV infection, which method comprises administering to said patient an effective amount of a benzodiazepine derivative of formula (I), or a pharmaceutically acceptable salt thereof,



wherein:

- R¹ represents C₁₋₆ alkyl, aryl or heteroaryl;
- R² represents hydrogen or C₁₋₆ alkyl;
- each R³ is the same or different and represents halogen, hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, amino, mono(C₁₋₆ alkyl)amino, di(C₁₋₆ alkyl)amino, nitro, cyano, -CO₂R', -CONR'R'', -NH-CO-R', -S(O)R', -S(O)₂R', -NH-S(O)₂R', -S(O)NR'R'' or -S(O)₂NR'R'', wherein each R' and R'' is the same or different and represents hydrogen or C₁₋₆ alkyl;
- n is from 0 to 3;
- R⁴ represents hydrogen or C₁₋₆ alkyl;
- R⁵ represents C₁₋₆ alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)-, heterocyclyl-(C₁₋₆ alkyl)-, aryl-

(C₁₋₆ hydroxyalkyl)-, heteroaryl-(C₁₋₆ hydroxyalkyl)-, carbocyclyl-(C₁₋₆ hydroxyalkyl)-, heterocyclyl-(C₁₋₆ hydroxyalkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or -XR⁶;

- X represents -CO-, -S(O)- or -S(O)₂-; and
- R⁶ represents C₁₋₆ alkyl, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)-, heterocyclyl-(C₁₋₆ alkyl)-, aryl-(C₁₋₆ alkyl)-O-, heteroaryl-(C₁₋₆ alkyl)-O-, carbocyclyl-(C₁₋₆ alkyl)-O-, heterocyclyl-(C₁₋₆ alkyl)-O- or -NR'R'' wherein each R' and R'' is the same or different and represents hydrogen, C₁₋₆ alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)- or heterocyclyl-(C₁₋₆ alkyl)-.

2. (Previously presented) A method according to claim 1 wherein:


- each R³ is the same or different and represents halogen, hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, amino, mono(C₁₋₆ alkyl)amino, di(C₁₋₆ alkyl)amino, nitro, cyano, -CO₂R', -CONR'R'', -NH-CO-R', -S(O)R', -S(O)₂R', -NH-S(O)₂R' or -S(O)NR'R'', wherein each R' and R'' is the same or different and represents hydrogen or C₁₋₆ alkyl;
- R⁵ represents C₁₋₆ alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)-, heterocyclyl-(C₁₋₆ alkyl)- or -XR⁶;
- X represents -CO-, -S(O)- or -S(O)₂-; and
- R⁶ represents C₁₋₆ alkyl, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)-, heterocyclyl-(C₁₋₆ alkyl)- or -NR'R'' wherein each R' and R'' is the same or different and represents hydrogen, C₁₋₆ alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C₁₋₆ alkyl)- or heteroaryl-(C₁₋₆ alkyl)-.

3. (Previously presented) A method according to claim 1, wherein R¹ is C₁₋₂ alkyl or aryl.

4. (Previously presented) A method according to claim 1, wherein R² is hydrogen.
5. (Previously presented) A method according to claim 1, wherein R³ is halogen, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, amino, mono(C₁₋₄ alkyl)amino or di(C₁₋₄ alkyl)amino.
6. (Previously presented) A method according to claim 5, wherein R³ is fluorine, chlorine, bromine, C₁₋₂ alkyl, C₁₋₂ alkoxy, C₁₋₂ alkylthio, C₁₋₂ haloalkyl, C₁₋₂ haloalkoxy, amino, mono(C₁₋₂ alkyl)amino or di (C₁₋₂ alkyl)amino.
7. (Previously presented) A method according to claim 1, wherein R⁴ is hydrogen or C₁₋₂ alkyl.
8. (Previously presented) A method according to claim 1, wherein R⁵ is C₁₋₆ alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C₁₋₄ alkyl)-, heteroaryl-(C₁₋₄ alkyl)-, carbocyclyl-(C₁₋₄ alkyl)-, heterocyclyl-(C₁₋₄ alkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or -XR⁶.
9. (Previously presented) A method according to claim 8, wherein R⁵ is C₁₋₄ alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, phenyl-(C₁₋₂ alkyl)-, heteroaryl-(C₁₋₂ alkyl)-, phenyl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or -XR⁶.
10. (Previously presented) A method according to claim 9, wherein R⁵ is C₁₋₄ alkyl, phenyl, thienyl, furanyl, isoxazolyl, pyridyl, cyclopentyl, cyclohexyl, benzothienyl, dihydrobenzofuranyl, phenyl-CH₂-, furanyl-CH₂-, phenyl-C(O)-C(O)-, thienyl-C(O)-C(O)- or -XR⁶.
11. (Previously presented) A method according to claim 1 wherein X is -CO- or -S(O)₂-.

12. (Previously presented) A method according to claim 1 wherein, when R^6 is a group - $NR'R''$ wherein each R' and R'' is the same or different and represents hydrogen, C_{1-4} alkyl, aryl, carbocyclyl, heterocyclyl, aryl-(C_{1-4} alkyl)- or heteroaryl-(C_{1-4} alkyl)-.
13. (Previously presented) A method according to claim 12, wherein when R^6 is a group - $NR'R''$ each R' and R'' is the same or different and represents hydrogen, C_{1-4} alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl- CH_2 -.
14. (Previously presented) A method according to claim 13, wherein when R^6 is a group - $NR'R''$ and one of R' and R'' is hydrogen.
15. (Previously presented) A method according to claim 1 wherein R^6 is C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-4} alkyl)-, heteroaryl-(C_{1-4} alkyl)-, carbocyclyl-(C_{1-4} alkyl)-, heterocyclyl-(C_{1-4} alkyl)-, aryl-(C_{1-4} hydroxyalkyl)-, heteroaryl-(C_{1-4} hydroxyalkyl)-, carbocyclyl-(C_{1-4} hydroxyalkyl)-, heterocyclyl-(C_{1-4} hydroxyalkyl)-, aryl-(C_{1-4} alkyl)- O -, heteroaryl-(C_{1-4} alkyl)- O -, carbocyclyl-(C_{1-4} alkyl)- O -, heterocyclyl-(C_{1-4} alkyl)- O - or - $NR'R''$.
16. (Previously presented) A method according to claim 15, wherein R^6 is C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, phenyl-(C_{1-2} alkyl)-, phenyl-(C_{1-2} alkyl)- O -, heteroaryl-(C_{1-2} alkyl)-, phenyl-(C_{1-2} hydroxyalkyl)-, heteroaryl-(C_{1-2} hydroxyalkyl)- or - $NR'R''$.
17. (Previously presented) A method according to claim 16, wherein R^6 is C_{1-4} alkyl, C_{1-4} alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(C_{1-2} alkyl)-, phenyl- CH_2 - $CH(OH)$ -, phenyl- $CH(OH)$ - CH_2 -, phenyl-(C_{1-2} alkyl)- O -, 1*H*-benzo[*d*]imidazol-2(3*H*)-onyl or - $NR'R''$.

18. (Previously presented) A method according to claim 1, wherein the benzodiazepine derivative of formula (I) is a benzodiazepine derivative of formula (Ia):



wherein:

- R^1 is phenyl or methyl;
- R^3 is methyl or chlorine;
- n is 0 or 1;
- R^4 is hydrogen or methyl;
- R^5 is phenyl- CH_2 -, furanyl- CH_2 -, thienyl-C(O)-C(O)- or - XR^6 ;
- X is -CO- or -S(O)₂-; and
- R^6 is C_{1-4} alkyl, C_{1-4} alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(C_{1-2} alkyl)-, phenyl- CH_2 -CH(OH)-, phenyl-CH(OH)- CH_2 -, phenyl-(C_{1-2} alkyl)-O-, 1H-benzo[*d*]imidazol-2(3*H*)-onyl or - $NR'R''$ wherein each R' and R'' is the same or different and represents hydrogen, C_{1-4} alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH_2)-,

the phenyl moiety in the group R^1 being unsubstituted or substituted by a single fluorine, chlorine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl or C_{1-2} haloalkoxy substituent;

the aryl moieties in the groups R^5 and R^6 being unsubstituted or substituted by 1,2 or 3 substituents selected from fluorine, chlorine, bromine, iodine, C_{1-4} alkyl, C_{2-4} acyl, hydroxy, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, amino, mono(C_{1-4}

alkyl)amino, di(C₁₋₄ alkyl)amino, nitro, -CO₂R', -S(O)₂R' and -S(O)₂NH₂, wherein R' represents C₁₋₂ alkyl;

the heteroaryl moieties in the groups R⁵ and R⁶ being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C₁₋₂ alkyl, C₁₋₂ haloalkyl and di(C₁₋₂ alkyl)amino; and

the heterocyclyl and carbocyclyl moieties in the R⁶ group being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl and nitro.

19. (Previously presented) A method according to claim 1, wherein the patient is a child under two years of age.
20. (Previously presented) A method according to claim 19 wherein said child suffers from chronic lung disease.
21. (Previously presented) A method according to claim 1 wherein the patient is an infant less than six years of age who was born after 32 weeks of gestation or less.
22. (Previously presented) A method according to claim 1, wherein the benzodiazepine derivative or salt thereof is administered intranasally or intrabronchially.
23. (Previously presented) A method according to claim 1, wherein an anti-inflammatory compound or an anti-influenza compound is further administered to the patient.
24. (Previously presented) A method according to claim 23 wherein the anti-inflammatory compound is budesonide or fluticasone.
25. (Previously presented) A method according to claim 23 wherein the anti-inflammatory compound is a leukotriene antagonist, phosphodiesterase 4 inhibitor or TNF alpha inhibitor.

26. (Previously presented) A method according to claim 23 wherein the anti-inflammatory compound is an interleukin 8 or interleukin 9 inhibitor.

27-30. (Canceled)

31. (Previously presented) An inhaler or nebuliser containing a medicament which comprises


- (a) a benzodiazepine derivative of formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof, and
- (b) a pharmaceutically acceptable carrier or diluent.

32. (Previously presented) A product comprising a compound of formula (I), or pharmaceutically acceptable salt thereof, as defined in claim 1, and an anti-inflammatory compound, or an anti-influenza compound.

33. (Previously presented) A method of treating a patient suffering from or susceptible to concomitant RSV and influenza infections, which method comprises administering to said patient an effective amount of a product according to claim 32.

34. (Previously presented) A method of treating a patient suffering from or susceptible to human metapneumovirus, measles, parainfluenza viruses, mumps, yellow fever virus (B5 strain), Dengue 2 virus or West Nile virus, which method comprises administering to said patient an effective amount of a compound of formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof.

35. (Original) A benzodiazepine derivative of formula (Ib), or a pharmaceutically acceptable salt thereof



wherein:

- R^1 represents C_{1-6} alkyl, aryl or heteroaryl;
- R^2 represents hydrogen, C_{1-6} alkyl;
- each R^3 is the same or different and represents halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, amino, mono(C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, nitro, cyano, $-CO_2R'$, $-CONR'R''$, $-NH-CO-R'$, $-S(O)R'$, $-S(O)_2R'$, $-NH-S(O)_2R'$, $-S(O)NR'R''$ or $-S(O)_2NR'R''$, wherein each R' and R'' is the same or different and represents hydrogen or C_{1-6} alkyl;
- n is from 0 to 3;
- R^4 represents hydrogen or C_{1-6} alkyl;
- $R^{5'}$ represents C_{3-6} alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)-, heterocyclyl-(C_{1-6} alkyl)-, aryl- $C(O)-C(O)-$, heteroaryl- $C(O)-C(O)-$, carbocyclyl- $C(O)-C(O)-$, heterocyclyl- $C(O)-C(O)-$ or $-X'$, provided that when $R^{5'}$ is heteroaryl it is not 2-quinaldyl or 6-chloro-pyrazinyl, when $R^{5'}$ is heteroaryl-(C_{1-6} alkyl)- it is not 2-indolylmethyl, 2-(3-indolyl)ethyl or 2-furanylmethyl, when $R^{5'}$ is aryl it is not unsubstituted phenyl and when $R^{5'}$ is aryl-(C_{1-6} alkyl)- it is not unsubstituted phenyl-(C_{1-2} alkyl)- or 4-chlorophenyl-(C_{2-3} alkyl)-;
- X' represents $-CO-R^{6'}$, $-S(O)-R^{6''}$ or $-S(O)_2-R^{6'''}$;
- $R^{6'}$ represents C_1 alkyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)-, heterocyclyl-(C_{1-6} alkyl)-, aryl-(C_{1-6} alkyl)- $O-$, heteroaryl-(C_{1-6} alkyl)- $O-$, carbocyclyl-(C_{1-6} alkyl)- $O-$, heterocyclyl-(C_{1-6} alkyl)- $O-$ or $-NR'R''$ wherein each R' and R'' is the same or different and represents hydrogen, C_{1-6} alkyl, carbocyclyl, heterocyclyl,

aryl, heteroaryl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)- or heterocyclyl-(C₁₋₆ alkyl)-, provided that (a) when R^{6/} is aryl it is not unsubstituted naphthyl, unsubstituted phenyl, mono-halophenyl, 4-methylphenyl, 4-methoxyphenyl, 4-hydroxyphenyl, 4-trifluoromethylphenyl, 4-nitrophenyl, 4-cyanophenyl, 4-n-propylphenyl, 4-t-butylphenyl, 4-n-pentylphenyl, 4-dimethylaminophenyl, 4-methylthiophenyl, 3-trifluoromethylthiophenyl, 3,4-dimethoxyphenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2,3,4,5,6-pentafluorophenyl, 4-chloro-2-aminophenyl or 4-1,1-dimethylethylphenyl, (b) when R^{6/} is heteroaryl it is not 2-pyrrolyl, 2-pyrazinyl, 2-quinaldyl, 2-quinoxalinyl, 1-methylindonly, 2-methyl-indolyl, 2-benzofuranyl, 2-benzothienyl, 3-thienyl, 3-indolyl, unsubstituted 2-indolyl, 5-fluoroindol-2-yl, 5-chloroindol-2-yl, 5-bromoindol-2-yl, 5-hydroxyindol-2-yl or 5-methoxyindol-2-yl, (c) when R^{6/} is aryl-(C₁₋₆ alkyl)- it is not 4-thianaphthene-(CH₂)-, unsubstituted phenyl-(CH₂)-, 4-trifluoromethylphenyl-(CH₂)-, unsubstituted phenyl-(CH₂)₃-, monotrifluoromethylphenyl-(CH₂)₂-, 3-methoxyphenyl-(CH₂)₂-, 4-chloro-2-aminophenyl-(CH₂)₂-, 2,4-dichlorophenyl-(CH₂)₂-, monochlorophenyl-(CH₂)₂-, 2,4-trifluoromethyl phenyl-(CH₂)₂-, 4-cyanophenyl-(CH₂)₂- or 3-cyanophenyl-(CH₂)₂-, (d) when R^{6/} is heteroaryl-(C₁₋₆ alkyl)- it is not indolyl-(CH₂)_x-, wherein x is 1, 2, 3, unsubstituted furanyl-(CH₂)₂-, unsubstituted thienyl-(CH₂)₃- (e) when R^{6/} is carbocyclyl it is not cyclohexyl, (f) when R^{6/} is carbocyclyl-(C₁₋₆ alkyl)- it is not unsubstituted cyclohexyl-(CH₂)₁₋₃-, (g) when R^{6/} is heterocyclyl it is not N-pyrrolidinyl or 2-dihydrobenzofuranyl, (h) when R^{6/} is aryl-(C₁₋₆ alkyl)-O- it is not unsubstituted phenyl-(CH₂)-O-, and (i) when R' is hydrogen, R'' is not unsubstituted phenyl, 4-halophenyl, 3-halophenyl, methoxyphenyl, nitrophenyl, 2-chlorophenyl, 4-methylphenyl, dichlorophenyl, 3,5-dimethylphenyl, 3-methylphenyl, 3-cyanophenyl, 3-aminophenyl, 3-aminocarbonylphenyl, 3-benzoic acid, 3-benzoic acid ethyl ester, 6-amino-3-pyridyl, 5-(2-chloro)pyridyl, 5-(2-methoxy)pyridyl, 5-indanyl, unsubstituted cyclohexyl, 1,1-dimethylethyl, unsubstituted phenyl-CH₂-, unsubstituted naphthyl or benzotriazol-3-yl and when R' is methyl, R'' is not cyclopropylbenzene;

- R^{6//} represents C₁₋₆ alkyl, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆

alkyl)-, heterocyclyl-(C₁₋₆ alkyl)-, aryl-(C₁₋₆ alkyl)-O-, heteroaryl-(C₁₋₆ alkyl)-O-, carbocyclyl-(C₁₋₆ alkyl)-O-, heterocyclyl-(C₁₋₆ alkyl)-O- or -NR'^{6//}R'' wherein each R' and R'' is the same or different and represents hydrogen, C₁₋₆ alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)- or heterocyclyl-(C₁₋₆ alkyl)-; and

- R^{6//} represents C₁₋₆ alkyl, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)-, heterocyclyl-(C₁₋₆ alkyl)-, aryl-(C₁₋₆ alkyl)-O-, heteroaryl-(C₁₋₆ alkyl)-O-, carbocyclyl-(C₁₋₆ alkyl)-O-, heterocyclyl-(C₁₋₆ alkyl)-O- or -NR'R'' wherein each R' and R'' is the same or different and represents hydrogen, C₁₋₆ alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)- or heterocyclyl-(C₁₋₆ alkyl)-, provided that when R^{6//} is aryl it is not 4-methylphenyl, provided that the compound of formula (Ib) is not N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide.


36. (Original) A benzodiazepine derivative according to claim 35 wherein:

- R^{5/} is C₃₋₆ alkyl, C₃₋₆ cycloalkyl, heterocyclyl, C₃₋₆ cycloalkyl-(C₁₋₆ alkyl), aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or -X';
- X' is -CO-R^{6/}, -S(O)-R^{6//} or -S(O)₂-R^{6///};
- R^{6/} is C₁ alkyl, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkylthio, heterocyclyl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-O-, carbocyclyl-(C₁₋₆ alkyl)-O-, heterocyclyl-(C₁₋₆ alkyl)-O- or -NR'R'' wherein each R' and R'' is the same or different and represents hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, heterocyclyl, carbocyclyl-(C₁₋₆ alkyl)- or heterocyclyl-(C₁₋₆ alkyl)-;
- R^{6//} represents C₁₋₆ alkyl, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)-, heterocyclyl-(C₁₋₆ alkyl)-, aryl-(C₁₋₆ alkyl)-O-, heteroaryl-(C₁₋₆ alkyl)-O-, carbocyclyl-(C₁₋₆ alkyl)-O-, heterocyclyl-(C₁₋₆ alkyl)-O- or -NR'R'' wherein each R' and R'' is the same or different and represents hydrogen, C₁₋₃ alkyl, heterocyclyl, heteroaryl, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)- or heterocyclyl-(C₁₋₆ alkyl)-; and

- $R^{6//}$ is C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{3-6} cycloalkyl, heterocyclyl, C_{3-6} cycloalkyl-(C_{1-6} alkyl)-, heterocyclyl-(C_{1-6} alkyl)-, aryl-(C_{1-6} alkyl)-O-, heteroaryl-(C_{1-6} alkyl)-O-, carbocyclyl-(C_{1-6} alkyl)-O-, heterocyclyl-(C_{1-6} alkyl)-O- or -NR'R'' wherein each R' and R'' is the same or different and represents hydrogen, C_{1-6} alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl), carbocyclyl-(C_{1-6} alkyl)- or heterocyclyl-(C_{1-6} alkyl)-.

37. (Previously presented) A benzodiazepine derivative according to claim 35 wherein R^2 is hydrogen.

38. (Original) A benzodiazepine derivative of formula (Ic), or a pharmaceutically acceptable salt thereof,



wherein:

- R^1 is phenyl or methyl;
- R^3 is methyl or chlorine;
- n is 0 or 1;
- R^4 is hydrogen or methyl;
- $R^{5'}$ is phenyl- CH_2 - thienyl-C(O)-C(O)- or -X';
- X' is -CO-R^{6'}, -CONR'R'', -S(O)₂R^{6'''} or -S(O)₂-NR₂R₃; and
- $R^{6'}$ is C_1 alkyl, C_{1-4} alkoxy, benzodioxinyl, 9H-fluoren-9-onyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, cyclopentyl, piperazinyl, piperidinyl, morpholinyl, phenyl- CH_2 -CH(OH)-, phenyl-CH(OH)-CH₂-, phenyl-(C_2 alkyl)-O- or 1*H*-benzo[*d*]imidazol-2(3*H*)-only;

- $R^{6''}$ is C_{1-4} alkyl, C_{1-4} alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(C_{1-2} alkyl)-, phenyl- $CH_2-CH(OH)-$, phenyl- $CH(OH)-CH_2-$, phenyl-(C_{1-2} alkyl)- $O-$ or $1H$ -benzo[d]imidazol-2($3H$)-only;

- each R' and R'' is the same or different and represents hydrogen, C_{1-4} alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH_2)-; and

- each R_i and R_{ii} is the same or different and represents hydrogen, C_{1-4} alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH_2)-, wherein:

the phenyl moiety in the group R^1 being unsubstituted or substituted by a single fluorine, chlorine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl or C_{1-2} haloalkoxy substituent;

the aryl moieties in the groups R^{5i} , R^{6i} and $R^{6'''}$ being unsubstituted or substituted by 1,2 or 3 substituents selected from fluorine, chlorine, bromine, iodine, C_{1-4} alkyl, C_{2-4} acyl, hydroxy, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-6} haloalkyl, C_{1-4} haloalkoxy, amino, mono(C_{1-4} alkyl)amino, di(C_{1-4} alkyl)amino, nitro, $-CO_2R'$, $-S(O)_2R'$ and $-S(O)_2NH_2$, wherein R' represents C_{1-2} alkyl;

the heteroaryl moieties in the groups R^{5i} , R^{6i} and $R^{6'''}$ being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} haloalkyl and di(C_{1-2} alkyl)amino;


the heterocyclyl and carbocyclyl moieties in the $R^{6'''}$ group being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl and nitro;

the aryl, heteroaryl and carbocyclyl moieties in the R' and R'' being unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl and nitro; and

the aryl, heteroaryl and carbocyclyl moieties in the R_i and R_{ii} being unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl and nitro,


provided that the compound of formula (Ic) is not N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide.

39. (Original) A benzodiazepine derivative of formula (Id), or pharmaceutically acceptable salts thereof



wherein R^{6*} is an aryl group which is unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C₁₋₆ alkyl, C₂₋₇ acyl, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, nitro, cyano, carbamoyl, mono(C₁₋₆ alkyl)carbamoyl, di(C₁₋₆ alkyl)carbamoyl, amino, mono(C₁₋₆ alkyl)amino, di(C₁₋₆ alkyl)amino, -CO₂R', -CONR'R'', -S(O)R', -S(O)₂R', -S(O)NR'R'', -S(O)₂NR'R'', -NH-S(O)₂R' or -NH-CO-R', wherein each R' and R'' is the same or different and represents hydrogen or C₁₋₆ alkyl, provided that R^{6*} is not a 4-chlorophenyl group.

40. (Original) A benzodiazepine derivative of formula (Ie) or a pharmaceutically acceptable salts thereof



wherein R'* is an aryl group which is unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy and nitro.

41. (Original) 1,1-Diethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-butyramide

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-isobutyramide

2,2-Dimethyl-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide

Cyclopentanecarboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

Cyclohexanecarboxylic acid 2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

Piperidine-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

Morpholine-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

4-Methyl-piperazine-1-carboxylic acid -(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

Benzo[b]thiophene-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

Isoxazole-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

Benzo[b]thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-methanesulfonamide

Propane-1-sulfonic acid-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

Butane-1-sulfonic acid-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-isobutyramide

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-isonicotinamide

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide

N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide

(S)-2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

(S)-1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

2-Chloro-4-methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

1-(4-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

2-Methoxy-4-methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

4-Methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)terephthalamic acid methyl ester

5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

3-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-terephthalamic acid methyl ester

2-Methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

4-Amino-5-chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

(S)-2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

(S)-5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-5-sulfamoyl-benzamide

1-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

1-Cycloheyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

1-Ethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

1-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

4,5-Dimethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide

Piperidine-1-carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide

N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-isobutyramide

Cyclohexanecarboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide

Piperidine-1-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide

N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]isonicotinamide

N-[5-(3-Methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-isobutyramide

Cyclohexanecarboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide

Piperidine-1-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide

Piperidine-4-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide

Cyclohexanecarboxylic acid (8-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

6-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide

Pyridine-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

1H-Pyrazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

6-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide

2-Ethoxy-naphthalene-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

9-Oxo-9H-fluorene-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

2-Oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid tert-butyl ester

(S)-6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

(S)-4,5-Dibromo-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

(S)-3-Methoxy-naphthalene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide
(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid methyl ester
(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid ethyl ester
(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid isobutyl ester
2-Oxo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-thiophene-2-yl-acetamide,
or a pharmaceutically acceptable salt thereof.

42. (Canceled)
43. (Previously presented) A pharmaceutical composition comprising a benzodiazepine derivative according to Claim 31, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluant or carrier.
44. (Previously presented) A composition comprising an optically active isomer of a benzodiazepine derivative according to Claim 31.
45. (Previously presented) A composition according to claim 43 which is in the form of a tablet, troche, lozenge, aqueous or oily suspension, dispersible powders or granules.
46. (New) A process for preparing a benzodiazepine derivative of the formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof, which process comprises:
 - (a) reacting 2-amino-benzophenone with bromoacetyl bromide, or an equivalent reagent, followed by ring closure with ammonia;
 - (b) protecting the NH group on the thus obtained compound by reacting with a base and an alkylating agent;
 - (c) reacting the protected intermediate thereby obtained with a base in a suitable solvent, to obtain thereby an oxime intermediate;

- (d) converting the thus obtained oxime intermediate into a corresponding racemic primary amine;
- (e) carrying out dynamic kinetic resolution on the racemic amine in the presence of a suitable optically active acid and a suitable aldehyde to precipitate a salt of the (S)-amine.

47. (New) A process according to claim 46, which further comprises:

- (f) transforming the optically active amine obtained in step (e) into an amide or urea.

48. (New) A process according to claim 46 wherein the protecting group introduced in step (b) is 4-methoxy-benzyl.

49. (New) A process according to claim 46, wherein the benzodiazepine derivative of the formula (I) is (S)-1-(2-fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea or (S)-4-methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide.